--- title: "Royalty Pharma (RPRX) stock: news and investor profile" url: "https://aibio.space/companies/royalty-pharma/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Royalty Pharma plc (NASDAQ: RPRX), United States. The directory classifies it as Pharmaceuticals: Major." --- RPRX Royalty Pharma plc NASDAQ · United States # Royalty Pharma (RPRX) news Debt Financing · 2026-05-28 ## [Royalty Pharma signs new $1.8 billion revolving credit facility maturing in 2031](https://aibio.space/news/royalty-pharma-signs-new-1-8-billion-revolving-credit-facility/) Royalty Pharma signed a $1.8 billion unsecured revolving credit facility maturing May 22, 2031, and repaid its 2021 facility in full. The covenants cap funded debt at 4.00 times Adjusted EBITDA, and the exhibit names a different borrower from the 8-K. ## Latest Royalty Pharma news 1. 2025-09-02 Financings [Zenas BioPharma signs royalty financing with Royalty Pharma for up to $300 million](https://aibio.space/news/zenas-biopharma-signs-royalty-financing-royalty-pharma-up-300-million/) Zenas BioPharma sold Royalty Pharma a share of future obexelimab revenue for up to $300 million. It received $75 million at closing, and the other three $75 million payments depend on a Phase 3 milestone and two FDA approvals. The company says the cash lasts into the first quarter of 2027. 2. 2025-09-02 Mergers [Zenas BioPharma signs Royalty Pharma funding deal worth up to $300 million](https://aibio.space/news/zenas-biopharma-signs-royalty-pharma-funding-deal-worth-up-300-million/) Royalty Pharma will pay $75 million upfront for a 5.5% royalty on worldwide net sales of obexelimab, with three more $75 million payments tied to milestones. 3. 2025-05-19 Mergers [Royalty Pharma completes acquisition of RP LLC for $200,000,000 cash and 24,530,266 Class E shares](https://aibio.space/news/royalty-pharma-completes-acquisition-rp-llc-200-000-000-cash-24-530/) Royalty Pharma Holdings Ltd also assumed a $380 million term loan facility. The 8-K reports a loan amendment with Bank of America, N.A., an exchange agreement and amended articles of association. ## Royalty Pharma at a glance - **Ticker**: RPRX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $837.0 million ### Related companies - [Opus Genetics](https://aibio.space/companies/opus-genetics/) NASDAQ: IRD - [Ardelyx](https://aibio.space/companies/ardelyx/) NASDAQ: ARDX - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) NASDAQ: BCAX - [Sagimet Biosciences](https://aibio.space/companies/sagimet-biosciences/) NASDAQ: SGMT - [Annovis Bio](https://aibio.space/companies/annovis-bio/) NYSE: ANVS - [Biogen](https://aibio.space/companies/biogen/) NASDAQ: BIIB - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [Prestige Consumer Healthcare](https://aibio.space/companies/prestige-consumer-healthcare/) NYSE: PBH ### Also on NASDAQ - [Alkermes](https://aibio.space/companies/alkermes/) ALKS - [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) SXTP - [SANUWAVE Health](https://aibio.space/companies/sanuwave-health/) SNWV - [Cryoport](https://aibio.space/companies/cryoport/) CYRX - [PMV Pharmaceuticals](https://aibio.space/companies/pmv-pharmaceuticals/) PMVP - [Envoy Medical](https://aibio.space/companies/envoy-medical/) COCH ## What Royalty Pharma does Royalty Pharma says it is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the industry. It holds royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Johnson & Johnson's Tremfya, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, and royalties on 20 development-stage product candidates. In 2025 it generated $3.3 billion of Portfolio Receipts, which it defines as royalty receipts plus milestones and other contractual receipts. It announced transactions with a total potential value of $4.7 billion and deployed $2.6 billion of cash in 2025. The company estimates the biopharmaceutical royalty market reached $10.0 billion in transaction value in 2025, and it says it holds approximately 48% of royalty transactions from 2020 through 2025. Royalty Pharma describes royalties as non-dilutive capital that lets biotechnology companies keep operational control of their programs. The company was founded in 1996. | Product or program | What it is | Stage | |---|---|---| | Trikafta | Vertex cystic fibrosis medicine on which Royalty Pharma holds a royalty | commercial | | Trelegy | GSK product on which Royalty Pharma holds a royalty | commercial | | Tysabri | Biogen product on which Royalty Pharma holds a royalty | commercial | | Amvuttra | Alnylam product on which Royalty Pharma holds a royalty | commercial | | Trodelvy | Gilead product on which Royalty Pharma holds a royalty | commercial | Summarised from the company's [10-K filed Feb 11, 2026](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm). ## Royalty Pharma annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.38 billion](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | [$2.26 billion](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | | Research and development | [$452.0 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | [$2.0 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | | Net income (loss) | [$770.9 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | [$859.0 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | | Cash from operations | [$2.49 billion](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | [$2.77 billion](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | | Cash and equivalents | [$618.7 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000015/) | [$929.0 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | | Short-term investments | [$18.8 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000015/) | [$58.2 million](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $812.0 million, plus short-term investments of $25.0 million, $837.0 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Royalty Pharma What is the ticker symbol of Royalty Pharma? Royalty Pharma plc trades under the ticker RPRX on NASDAQ. Where is Royalty Pharma listed? Royalty Pharma plc is listed on NASDAQ. Our directory also records these other listings: BMV:RPRX/N; DUS:RPD; FWB:RPD; GETTEX:RPD; HAM:RPD; HAN:RPD; LS:A2P62D; LSX:A2P62D; MUN:RPD; SWB:RPD; TRADEGATE:RPD; XETR:RPD. What is the SEC CIK of Royalty Pharma? The SEC Central Index Key (CIK) for Royalty Pharma plc is 1802768. Its filings are on SEC EDGAR. How many shares does Royalty Pharma have outstanding? 388,132,400 shares as of 2020-11-10, per the cover page of its 10-Q filed 2020-11-12. Which country or territory is Royalty Pharma listed under? Our directory records Royalty Pharma plc under United States. What does Royalty Pharma do? Our directory classifies Royalty Pharma plc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Royalty Pharma? The ISIN recorded for Royalty Pharma plc is GB00BMVP7Y09. Does aibio.space cover Royalty Pharma? aibio.space lists Royalty Pharma plc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Royalty Pharma incorporated? SEC records list its state or country of incorporation as X0. What does Royalty Pharma develop? Royalty Pharma says it is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the industry. It holds royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Biogen's Tysabri and Spinraza, Roche's Evrysdi, Johnson & Johnson's Tremfya, Servier's Voranigo, Gilead's Trodelvy, Amgen's Imdelltra and Alnylam's Amvuttra, and royalties on 20 development-stage product candidates. What is Trikafta from Royalty Pharma? Trikafta: Vertex cystic fibrosis medicine on which Royalty Pharma holds a royalty Stage: commercial. What is Trelegy from Royalty Pharma? Trelegy: GSK product on which Royalty Pharma holds a royalty Stage: commercial. What was Royalty Pharma's revenue last year? $2.38 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Royalty Pharma profitable? Royalty Pharma plc reported net income of $770.9 million for the fiscal year ended Dec 31, 2025, and generated $2.49 billion of cash from operations, per its annual report to the SEC. How much does Royalty Pharma spend on research and development? $452.0 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Royalty Pharma Members talk about Royalty Pharma (RPRX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Royalty Pharma, newest first. Each line links the filing it comes from. 1. 2025-05-19 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,2.03,5.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1802768/000095010325006186/dp228958_8k.htm) 2. 2025-01-15 Mergers Filed documents for a merger or acquisition. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1802768/000095010325000523/dp223466_425.htm) 3. 2025-01-13 Financings Announced a share repurchase program. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1802768/000119312525005038/d919433dex991.htm) 4. 2025-01-10 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1802768/000095010325000393/dp223331_ex9901.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RPRX on TradingView](https://www.tradingview.com/symbols/NASDAQ-RPRX/). ## SEC filings and registration - **SEC name**: Royalty Pharma plc - **CIK**: 1802768 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RPRX (Nasdaq) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 110 EAST 59TH STREET, NEW YORK, NY, 10022 - **Phone**: (212) 883-0200 - **Shares outstanding**: 388,132,400 as of 2020-11-10 (10-Q filed 2020-11-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000015/rprx-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1802768/000119312526257432/d855771d8k.htm) filed 2026-06-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1802768/000119312526245163/d131735d8k.htm) filed 2026-05-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000009/rprx-20260331.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260506.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1802768/000119312526152145/d871473d8k.htm) filed 2026-04-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1802768/000114036126014239/ny20066979x1_def14a.htm) filed 2026-04-10 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001802768), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Royalty Pharma plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RPRX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Royalty Pharma plc - **Ticker**: RPRX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: GB00BMVP7Y09 - **Other listed symbols**: BMV:RPRX/N; DUS:RPD; FWB:RPD; GETTEX:RPD; HAM:RPD; HAN:RPD; LS:A2P62D; LSX:A2P62D; MUN:RPD; SWB:RPD; TRADEGATE:RPD; XETR:RPD - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RPRX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/royalty-pharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Royalty Pharma (RPRX) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/royalty-pharma/